The agreement accelerates Novartis’ ability to use data and digital to transform commercial models, ensuring more meaningful interactions with healthcare providers
SHYFT Analytics' Intelligent Platform for Life Sciences has been selected by Novartis to support the commercialisation of its key therapies in Europe.
Novartis will use the following SHYFT solutions:
Together, these solutions simplify and accelerate the aggregation, assimilation and analysis of scores of disparate data sets that inform commercial sales and medical education programmes.
“Pharma companies are acutely aware of the tremendous demands on healthcare professionals’ time. Every minute is important, and every interaction we have with a healthcare professional must be efficient, relevant and impactful,” said Bertrand Bodson, Chief Digital Officer at Novartis.
“Medidata and SHYFT have come together in a way that allows us to share data and insights seamlessly across our Clinical Development and Commercial teams."
"We are committed to reimagining medicine with data and digital, and this technology helps us do that by supporting our pharma sales reps with intelligence-driven ‘next-best-actions’ so they can make the 100,000 interactions they have with HCPs every day as personalized and meaningful as possible,” said Bodson.
SHYFT is a Medidata company and Novartis’ new partnership with SHYFT extends its existing collaboration with Medidata in support of its clinical trials and commercialisation programmes. .
“Novartis is leading the charge on accelerating value and optimizing outcomes in life sciences because they approach innovation with the care, forethought, and agility typically found in much smaller organizations,” said Zack King, EVP Medidata and President of SHYFT.
“We are thrilled about our role in Novartis’ path toward digital transformation and are honored to partner with them as they take on some of the biggest global challenges in healthcare.”